Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Other Non-Current Liabilities came in at $453000.0 in Q1 2026, down 47.08% year-on-year from $856000.0 in Q1 2025, and down 18.53% quarter-over-quarter from $556000.0 in Q4 2025.
Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Foghorn Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $453000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 47.08% year-over-year to $453000.0 in Q1 2026; TTM through Mar 2026 was $453000.0, a 47.08% decrease from a year earlier, with the FY2025 full-year figure at $556000.0, changed N/A from the prior year.
- Other Non-Current Liabilities fell to $453000.0 in Q1 2026 per FHTX's latest filing, from $556000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $856000.0 in Q1 2025 and bottomed at $29000.0 in Q4 2022.
- The 3-year median for Other Non-Current Liabilities is $453000.0 (2026), against an average of $396555.6.
- Across the five-year window, Other Non-Current Liabilities plunged 79.72% in 2022 and sank 47.08% in 2026, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $29000.0 in 2022, then jumped by 1817.24% to $556000.0 in 2025, then fell by 18.53% to $453000.0 in 2026.
- Per Business Quant, the three latest FHTX Other Non-Current Liabilities figures stand at $453000.0 (Q1 2026), $556000.0 (Q4 2025), and $656000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 453,000.00 |
| Dec 31, 2025 | 556,000.00 |
| Sep 30, 2025 | 656,000.00 |
| Jun 30, 2025 | 757,000.00 |
| Mar 31, 2025 | 856,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 58,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 116,000.00 |
| Dec 31, 2021 | 143,000.00 |
| Sep 30, 2021 | 171,000.00 |